Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA dates
PRAX•Upcoming readout and launch timing
The company expects a Q4 2026 topline readout from EMERALD, a Phase 3 study of relutrigine in phenotypic DEEs with about 200 patients.
Praxis also cited cash runway into 2028 while preparing for a potential ulixacaltamide launch in early 2027.
Investor deck highlights late-stage CNS programs
Praxis Precision Medicines highlighted four late-stage CNS programs, citing portfolio peak sales potential above USD 20 billion.
Ulixacaltamide for essential tremor is under FDA review with a January 2027 PDUFA date; the company cited two positive Phase 3 studies.
Relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathies has an FDA target action date of December 27, 2026.
